English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/62260
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Optimisation of mesenchymal stromal cells karyotyping analysis: Implications for clinical use

AuthorsMuntión, Sandra; Sánchez-Guijo, Fermín M.; Carrancio, Soraya; Villarón, Eva M.; López, O.; Díez-Campelo, María; San Miguel, Jesús F. ; Cañizo, María Consuelo del
Issue Date2012
PublisherWiley-Blackwell
CitationTransfusion Medicine 22(2): 122-127 (2012)
Abstract[Purpose]: The aim of this study was to optimise the yield of metaphases in mesenchymal stromal cells (MSC) in vitro cultures and to study the karyotype of MSC expanded in good manufacturing practice (GMP) conditions for clinical use. [Background]: MSC are being increasingly used in clinical trials for a number of diseases. Biosafety demonstration in all cases is mandatory. Unfortunately, current standard karyotyping methods fail to obtain enough number of evaluable metaphases. [Methods and materials]: In the present work, to optimise the yield of metaphases in MSC expanded in vitro, we have tested several conditions by modifying colcemid concentration (we have tested 0·01, 0·05 and 0·1 μg mL -1) and exposure time (during 5, 15 and 24 h). We further applied these optimised conditions to 61 MSC expansions in GMP conditions for clinical use. [Results]: Our results show that the highest number of metaphases was obtained when MSC were incubated with 0·05 μg mL -1 of colcemid overnight (15 h), compared to the remaining experimental conditions. In most cases (59/61 cases) enough number of metaphases was obtained. And what is more relevant, only in one case a karyotypic abnormality was found (trisomy of chromosome 10), and cells were subsequently discarded for clinical use. [Conclusion]: We describe here an optimal method to obtain enough number of metaphases for karyotype analysis of in vitro expanded MSCs, what is essential for their clinical use in cell therapy programmes. © 2012 The Authors. Transfusion Medicine © 2012 British Blood Transfusion Society.
URIhttp://hdl.handle.net/10261/62260
DOI10.1111/j.1365-3148.2012.01134.x
Identifiersissn: 0958-7578
e-issn: 1365-3148
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.